Headache : A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution
Caronna, Edoardo (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ballvé, Alejandro (Hospital Universitari Vall d'Hebron)
Llaurado, Arnau (Hospital Universitari Vall d'Hebron)
Gallardo, Víctor J.. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ariton, Diana María (Hospital Universitari Vall d'Hebron)
Lallana, Sofia (Hospital Universitari Vall d'Hebron)
López Maza, Samuel (Hospital Universitari Vall d'Hebron)
Olivé-Gadea, Marta (Hospital Universitari Vall d'Hebron)
Quibus, Laura (Hospital Universitari Vall d'Hebron)
Restrepo, Juan Luis (Hospital Universitari Vall d'Hebron)
Rodrigo-Gisbert, Marc (Hospital Universitari Vall d'Hebron)
Vilaseca, Andreu (Hospital Universitari Vall d'Hebron)
Hernandez Gonzalez, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Martinez Gallo, Monica (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Alpuente, Alicia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Torres-Ferrús, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pujol Borrell, Ricard (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Álvarez Sabín, José (Hospital Universitari Vall d'Hebron)
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2020
Resum:	To define headache characteristics and evolution in relation to COVID-19 and its inflammatory response. This is a prospective study, comparing clinical data and inflammatory biomarkers of COVID-19 patients with and without headache, recruited at the Emergency Room. We compared baseline with 6-week follow-up to evaluate disease evolution. Of 130 patients, 74. 6% (97/130) had headache. In all, 24. 7% (24/97) of patients had severe pain with migraine-like features. Patients with headache had more anosmia/ageusia (54. 6% vs. 18. 2%; p < 0. 0001). Clinical duration of COVID-19 was shorter in the headache group (23. 9 ± 11. 6 vs. 31. 2 ± 12. 0 days; p = 0. 028). In the headache group, IL-6 levels were lower at the ER (22. 9 (57. 5) vs. 57. 0 (78. 6) pg/mL; p = 0. 036) and more stable during hospitalisation. After 6 weeks, of 74 followed-up patients with headache, 37. 8% (28/74) had ongoing headache. Of these, 50% (14/28) had no previous headache history. Headache was the prodromal symptom of COVID-19 in 21. 4% (6/28) of patients with persistent headache (p = 0. 010). Headache associated with COVID-19 is a frequent symptom, predictive of a shorter COVID-19 clinical course. Disabling headache can persist after COVID-19 resolution. Pathophysiologically, its migraine-like features may reflect an activation of the trigeminovascular system by inflammation or direct involvement of SARS-CoV-2, a hypothesis supported by concomitant anosmia.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Headache ; COVID-19 ; SARS-CoV-2 ; Prognosis ; Loss of smell
Publicat a:	Cephalalgia, Vol. 40 (november 2020) , p. 1410-1421, ISSN 1468-2982

DOI: 10.1177/0333102420965157
PMID: 33146036

12 p, 641.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats